title: Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.
abstract: Approaches to alter the native tropism of adenoviruses (Ads) are beneficial to increase their efficacy and safety profile. Liver tropism is important with regard to potential clinical toxicity in humans. Ad5/3 chimeras in which the Ad5 knob is substituted by the Ad3 knob, such as Ad5/3luc1, have been recently shown to increase infectivity of ovarian cancer cell lines and primary tumor cells, which express low levels of the coxsackie-adenovirus receptor (CAR), without increasing infectivity of liver cells. A novel strategy to address the problem of liver uptake and improve the tumor/liver ratio is genetic replacement of the Ad fiber shaft. Ad5.Ad3.SH.luc1 is an Ad5-based vector that contains the fiber shaft from Ad serotype 3 but the fiber knob from Ad serotype 5. To compare tumor/liver of Ad5.Ad3.SH.luc1 and Ad5/3luc1 in vivo, we created three different tumor and treatment models of ovarian cancer in mice, simulating intraperitoneal and intravenous administration of tumors. Ad5.Ad3.SH.luc1 displayed the lowest liver tropism of all viruses in all models tested. Intravenous administration of all viruses resulted in higher tumor transduction rates compared to intraperitoneal administration. Genetic shortening of the Ad5 fiber shaft significantly increases relative tumor/liver gene transfer. This could improve the effective tumor dose and reduce side effects, thereby increasing the bioavailability of therapeutic agents.
authors.affiliation: Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
authors.forename: Martina
authors.initials: M
authors.lastname: Breidenbach
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Rein
authors.forename: Minghui
authors.initials: M
authors.lastname: Wang
authors.forename: Dirk M
authors.initials: DM
authors.lastname: Nettelbeck
authors.forename: Akseli
authors.initials: A
authors.lastname: Hemminki
authors.forename: Ilya
authors.initials: I
authors.lastname: Ulasov
authors.forename: Angel R
authors.initials: AR
authors.lastname: Rivera
authors.forename: Maaike
authors.initials: M
authors.lastname: Everts
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
authors.forename: Joanne T
authors.initials: JT
authors.lastname: Douglas
authors.forename: David T
authors.initials: DT
authors.lastname: Curiel
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D045744:Cell Line, Tumor; D004847:Epithelial Cells / Q000378:metabolism; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008099:Liver / Q000378:metabolism*; D008156:Luciferases / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009928:Organ Specificity; D010051:Ovarian Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000378:metabolism; D011995:Recombination, Genetic; D012703:Serotyping; D014161:Transduction, Genetic; D023041:Xenograft Model Antitumor Assays
chemical_list: D011994:Recombinant Proteins; D008156:Luciferases